tallózása szerző szerint "Pócza, Tímea"

A találatok rendezése: Rendezés: Találatok:

  • A longevity study with enhancer substances (selegiline, BPAP) detected an unknown tumor-manifestation-suppressing regulation in rat brain 
    Knoll, József; Baghy, Kornélia; Eckhardt S; Ferdinandy, Péter; Garami, Miklós; Hársing, László Gábor; Hauser, Péter; Mervai, Zsolt; Pócza, Tímea; Schaff, Zsuzsa; Schuler, Dezső; Miklya, Ildikó (2017)
    AIMS: First proof to show that (-)-deprenyl/selegiline (DEP), the first selective inhibitor of MAO-B, later identified as the first beta-phenylethylamine (PEA)-derived synthetic catecholaminergic activity enhancer (CAE) ...
  • Gyermekkori központi idegrendszeri daganatok érújdonképződés-gátló kezelésének magyarországi eredményei a Kieran-sémával 
    Hauser, Péter; Vancso I; Pócza, Tímea; Schuler, Dezső; Garami, Miklós (2013)
    In Hungary a new oral antiangiogenic treatment was introduced in cases of primary chemoresistant or recurrent pediatric CNS tumors, called Kieran schedule. The early results of this treatment were analyzed. From 2010 at ...
  • Gyermekkori medulloblastoma in vitro vizsgálata 
    Pócza, Tímea (2017)
  • High expression of DNA methyltransferases in primary human medulloblastoma 
    Pócza, Tímea; Krenács, Tibor; Turányi, Eszter; Csáthy J; Jakab, Zsuzsanna; Hauser, Péter (2016)
  • mTOR Pathway As a Potential Target In a Subset of Human Medulloblastoma. 
    Pócza, Tímea; Sebestyén, Anna; Turányi, Eszter; Krenács, Tibor; Márk, Ágnes; Sticz TB; Jakab, Zsuzsanna; Hauser, Péter (2014)
    As mammalian Target of Rapamycin (mTOR) plays role in protein synthesis and metabolism, mTOR pathway activation is involved in the pathogenesis of several types of tumors. Our aim was to elucidate its role in medulloblastoma ...
  • Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis 
    Thompson, EM; Hielscher, T; Bouffet, E; Remke, M; Luu, B; Gururangan, S; McLendon, RE; Bigner, DD; Lipp, ES; Perreault, S; Cho, YJ; Grant, G; Kim, SK; Lee, JY; Rao, AA; Giannini, C; Li, KK; Ng, HK; Yao, Y; Kumabe, T; Tominaga, T; Grajkowska, WA; Perek-Polnik, M; Low, DC; Seow, WT; Chang, KT; Mora, J; Pollack, IF; Hamilton, RL; Leary, S; Moore, AS; Ingram, WJ; Hallahan, AR; Jouvet, A; Fevre-Montange, M; Vasiljevic, A; Faure-Conter, C;; Shofuda, T; Kagawa, N; Hashimoto, N; Jabado, N; Weil, AG; Gayden, T; Wataya, T; Shalaby, T; Grotzer, M; Zitterbart, K; Sterba, J; Kren, L; Hortobágyi, Tibor; Klekner, Álmos; Laszlo, B; Pócza, Tímea; Hauser, Péter; Schuller, U; Jung, S; Jang, WY; French, PJ; Kros, JM; van Veelen, MC; Massimi, L; Leonard, JR; Rubin, JB; Vibhakar, R; Chambless, LB; Cooper, MK; Thompson, RC; Faria, CC; Carvalho, A; Nunes, S; Pimentel, J; Fan, X; Muraszko, KM; Lopez-Aguilar, E; Lyden, D; Garzia, L; Shih, DJ; Kijima, N; Schneider, C; Adamski, J; Northcott, PA; Kool, M; Jones, DT; Chan, JA; Nikolic, A; Garre, ML; Van, Meir EG; Osuka, S; Olson, JJ; Jahangiri, A; Castro, BA; Gupta, N; Weiss, WA; Moxon-Emre, I; Mabbott, DJ; Lassaletta, A; Hawkins, CE; Tabori, U; Drake, J; Kulkarni, A; Dirks, P; Rutka, JT; Korshunov, A; Pfister, SM; Packer, RJ; Ramaswamy, V; Taylor, MD (2016)
    BACKGROUND: Patients with incomplete surgical resection of medulloblastoma are controversially regarded as having a marker of high-risk disease, which leads to patients undergoing aggressive surgical resections, so-called ...